Ovarian stimulation for fertility preservation in a woman with borderline serous ovarian tumor causing a large fluctuating subcutaneous fluid collection: a case report

Ranit Hizkiyahu1, Shannon Salvador2, Michael H. Dahan1,∗

1 Department of Obstetrics and Gynecology, Royal Victoria Hospital, McGill University, Montreal, QC H3L 4S8, Canada
2 Department of Obstetrics and Gynecology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada
∗Correspondence: dahanhaim@hotmail.com (Michael H. Dahan)

DOI: 10.31083/j. ceog4805193

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).

Submitted: 9 February 2021 Revised: 6 May 2021 Accepted: 17 May 2021 Published: 15 October 2021

Background: Fertility preservation in oncologic cases has increased exponentially during the last 15 years. Most of these cases occur in women with breast cancer or lymphoma. Rarely, the onco-fertility physician will have cases of young ovarian cancer patients who wish to cryopreserve their oocytes or embryos. Case: A previously undescribed presentation of a borderline serous ovarian tumor in a woman undergoing ovarian stimulation for fertility preservation. On the day of egg retrieval, a large subcutaneous fluid collection was noted. This fluid collection is possibly secondary to laparoscopic resection of the ovarian mass. Although, cancer recurrence has been noted at laparoscopic port entry sites and ovarian stimulation has been hypothesized to increase the risk of advancement of ovarian cancer cells, this is the first time in the medical literature that a supra-facial fluid collection occurred during gonadotropin stimulation, without ovarian hyperstimulation syndrome, in the context of ovarian malignancy. Our hypothesis is that during an operation before the stimulation cycle started, low malignant potential ovarian cells spread via the laparoscopy port to the subcutaneous space and grew in response to the gonadotropin stimulation. Conclusions: Being a borderline tumor, the fluid collection was self limited and did not re-occur with subsequent stimulations. However, in cases of frank ovarian malignancy and ovarian stimulation for fertility preservation cancer metastasis could occur to the sub-cutaneous space.

Keywords
Fertility preservation, Ovarian tumor, Ovarian stimulation, Fluid collection, Laparoscopy

1. Introduction

Fertility preservation in oncologic cases has increased exponentially during the last 15 years. Most of these cases occur in women with breast cancer or lymphoma [1, 2]. In these cases, ovarian stimulation and oocyte collection or cryopreservation of ovarian tissue are options to maintain fertility in the presence of impending gonadotoxic chemo or radiation therapy [3]. Rarely, the onco-fertility physician will have cases of young ovarian cancer patients who wish to cryopreserve their oocytes or embryos [4]. In such cases, ovarian tissue cryopreservation runs the risk of re-introducing the cancer if the tissue is subsequently returned to the patient. There are over 40 reported cases in the medical literature of ovarian stimulation and oocyte collection in women with ovarian cancer [5–9]. Most of these procedures were performed in women with serous borderline tumors, while some were in women with overt malignancies [9]. Controlled ovarian hyperstimulation poses a major concern of accelerating tumor growth [4], however, borderline ovarian tumors usually recur locally or on the contra-lateral ovary and rarely metastasize. Therefore, fertility preservation in patients who were diagnosed with or previously treated for borderline ovarian tumors is likely reasonable [10]. Whereas ovarian stimulation is usually followed by transvaginal or transabdominal oocyte collection, there are some reports of successful ex-vivo oocyte harvesting in patients with borderline ovarian tumor during the oncologic operation [5, 6].

Recurrence rates of borderline ovarian tumor are heavily affected by the type of primary surgery performed. Fertility-sparing surgery is associated with higher recurrence rates (0–25%) compared to the radical approach, where both adnexa are removed (0–5%) [11, 12]. In patients who experience recurrence after the fertility-sparing surgery, it is of major importance to assess their ovarian reserve and consider fertility preservation, since they are at increased risk of infertility even in case of a second fertility-sparing surgery [13]. Filippi et al. [8] reported two cases where ovarian stimulation and oocyte retrieval were performed prior to the second surgery, with a satisfactory number of oocytes collected and no detrimental effects on the ovarian lesions noted. Therefore, the author concluded that such a procedure is a feasible option. No evidence of tumor cell growth in-vivo with ovarian stimulation is currently in the medical literature. This may be due to the fact that the majority of these cases involved borderline tumors which are unlikely to produce invasive metastases. We will present the likely first case of ovarian stimulation which was associated with concomitant accumulation of supra-facial fluid that might represent a growth of ovarian tumor cells during the stimulation. The complication seen...
will be described for the first time in the medical literature. It occurred in a woman with a borderline serous tumor undergoing ovarian stimulation for fertility preservation.

2. Case report

A 30-years old nulligravida woman was referred for fertility preservation 6 months after undergoing right salpingo-oopherectomy due to ovarian torsion and rupture. During the surgery an omental biopsy was taken but the left ovary had a normal appearance. Lymph node dissection was not performed. Pathologic results revealed a borderline serous ovarian tumor, however the omental biopsy was negative for invasive tumor. At the time of diagnosis, her serum cancer antigen 125 (CA-125) level was 245 U/mL (normal range 0–35). She was told at that time, that there was a high risk of re-occurrence in the other ovary and she should consider fertility preservation. She presented to the fertility center and a transvaginal ultrasound scan demonstrated a 7.5 cm complex mass on the left side. Ovarian tissue with follicles was identified. A serum CA-125 level was 66 U/mL. The patient underwent counseling by the oncofertility team, discussing the risk of cancer advancing or spreading during ovarian stimulation and egg retrieval. Since the patient had a partner, she preferred to proceed with stimulation and embryo freezing. She presented to the fertility center. Baseline Blood tests before stimulation showed a serum Anti-Mullerian Hormone (AMH) 1.54 ng/mL (range 0.07–7.35 ng/mL, cut off for decreased ovarian reserve <1.50 ng/mL by the assay used), serum basal Follicle-stimulating hormone (FSH) 7.6 IU/L with a serum basal estradiol of 211 pmol/L. A new complex ovarian cyst was present measuring 3.3 cm in maximum diameter. The patient underwent controlled ovarian hyperstimulation over 7 days with a total of 2100 units of human menopausal gonadotropin (Menopur, Ferring, Montreal, Canada) (300 IU daily). She produced 4 follicles of 16–18 mm in mean diameter. The patient underwent fluid collection ran from the pubic symphysis to the upper abdomen crossing the midline. It was one centimeter in anterior posterior thickness and was well above the peritoneal cavity in a supra fascial location. Oocytes were retrieved. Referral to the Gynecologic Oncology (GYN) oncologist was made again. A decision was made to obtain a fluid sample for cytology and order an Magnetic resonance imaging (MRI) at the same time. An MRI was performed to delineate the fluid collection, 7 days after the oocyte retrieval at which point the fluid collection was gone (Fig. 2—MRI image). The fluid cytology had not yet been performed. During two subsequent stimulation cycles (1–2 weeks after collections), with the same protocol, no fluid was observed to collection in the supra peritoneal space. Removal of the recurrent ovarian mass again revealed a borderline ovarian serous tumor.
Borderline ovarian tumors are considered as low malignant potential tumors. However, they may relapse and, albeit rare, malignant transformation can occur. A micropapillary pattern is associated with adverse outcomes such as lower disease-free survival and the presence of invasive implants [10, 14]. Around 30% of borderline ovarian tumors are observed in patients younger than 40 years of age [15]. Therefore, patients who are diagnosed with borderline ovarian tumors are amenable to consideration of fertility preservation.

Fertility preservation in patients suffering from borderline ovarian tumors have been described in the literature [5, 7, 16]. Gonadotropin stimulation of ovarian tumor cells could in theory cause tumor cell growth and metastasis to occur. However, up until this point no proof of such has been noted. This was assumed to be due to the short duration of gonadotropin stimulation. However, this is the first time in the medical literature that a supra-facial large fluid collection occurred during ovarian stimulation of an ovarian tumor patient, with the absence of ascites or ovarian hyperstimulation syndrome. The subject had only 4 follicles stimulated, relatively low serum estradiol levels and no ascites was present. It is also extremely unlikely that ovarian hyperstimulation syndrome was present on the day of oocyte retrieval because it usually occurs several days later. Interestingly, the fluid collection was self-limited and disappeared post ovarian stimulation. Regrettably, this occurred prior to obtaining a cytological specimen of this fluid for assessment. Our hypothesis is that during the emergency operation for the cyst rupture, before the stimulation cycle started, low malignant potential ovarian cells spread via the laparoscopy port to the subcutaneous space, although of such we cannot be certain.

Morice and colleagues reported 3 cases of port-site implantation after laparoscopic treatment of a borderline ovarian tumor, which were treated by surgical resection of the port-site with good prognosis [17]. Berretta and colleagues reported 22 cases of port-site metastasis after laparoscopic management of borderline ovarian tumors, most of them were associated with serous histology [18]. In another case report, isolated subcutaneous implantation of a borderline mucinous ovarian tumor was diagnosed 9 days after the laparoscopic surgery [19]. Therefore, it is not unlikely to presume that tumor seeding could have occurred during the laparoscopic operation.

As for the fluid collection being induced by ovarian stimulation, several unique issues occurred. First of all, the fluid collection reabsorbed on its own and did not re-occur with the subsequent stimulation cycles. We suspect this reflects the propensity for low malignant potential tumors not to metastasize in an invasive fashion. Although, these tumors seed cells to the peritoneal cavity, these cells have a life cycle and undergo spontaneous apoptosis. We hypothesize this likely occurred to the cells causing the fluid collection in the subcutaneous space, however, no cytology specimen was obtained since the fluid reabsorbed prior to this being done. Whether ovarian stimulation increases invasive metastasis of low malignant potential ovarian tumors is unknown. There is a paucity of evidence regarding controlled ovarian hyperstimulation in patients with borderline ovarian tumor. This tumor has both receptors for estrogen as well as progesterone, and there may be detrimental effects of controlled ovarian hyperstimulation on borderline ovarian tumor growth [4]. It is possible that hormone production seen with ovarian stimulation may induce an apoptosis of these borderline ovarian tumor cells [4] or that they would have undergone apoptosis anyways, since this may be the nature of such a tumor. In future cases, use of an aromatase inhibitor may prevent growth of the tumor cells by decreasing endogenous estrogen levels and should have been considered in this case. Aromatase inhibition was not initiated with the stimulation protocol due to the propensity of low malignant potential tumor cells to not metastasize.

The exact cause of the subcutaneous fluid accumulation cannot be known with certainty because it reabsorbed itself prior to a cytological specimen being collected. However, the accumulation of subcutaneous fluid in a women undergoing ovarian stimulation is unique in the literature.

This case demonstrates a unique complication of ovarian stimulation that has not been previously reported in the medical literature. Reassuringly, the fluid collection was self-controlled and did not re-occur. This finding suggests that if caused by cells from the ruptured tumor, ovarian stimulation did not alter their life cycle and they likely continued to undergo apoptosis. As such, ovarian stimulation in borderline malignant ovarian tumors needs further study.

Author contributions

RH, SS and MHD made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work; drafted the work or revised it critically for important intellectual content; approved the version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity
of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The patient has given written consent to the inclusion of material pertaining to herself; The authors have fully anonymized the patient. Ethics approval for case reports is not required at our institution.

Acknowledgment
We wish to thank the patient for consenting to publication of this article.

Funding
This research received no external funding.

Conflict of interest
The authors declare no conflict of interest. MHD is the Editor in Chief of this journal, given his role as Editor in Chief, had no involvement in the peer-review of this article and has no access to information regarding its peer-review.

References
[1] Lefebvre T, Mirallié S, Lepertier F, Reignier A, Barrière P, Fréour T. Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type. Reproductive BioMedicine Online. 2018; 37: 201–207.
[2] von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schüiring AN, Bruckner T, et al. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reproductive Biomedicine Online. 2015; 31: 605–612.
[3] Hussein RS, Khan Z, Zhao Y. Fertility preservation in women: indications and options for therapy. Mayo Clinic Proceedings. 2020; 95: 770–783.
[4] Mangili G, Somigliana E, Giorgione V, Martinelli F, Filippi F, Petrella MC, et al. Fertility preservation in women with borderline ovarian tumours. Cancer Treatment Reviews. 2016; 49: 13–24.
[5] Bocca S, Dedmond D, Jones E, Stadmayer L, Oehninger S. Successful extracorporeal mature oocyte harvesting after laparoscopic oophorectomy following controlled ovarian hyperstimulation for the purpose of fertility preservation in a patient with borderline ovarian tumor. Journal of Assisted Reproduction and Genetics. 2011; 28: 771–772.
[6] de Carvalho BR, Cintra GF, Franceschi TM, Cabral JO, Resende LSDA, Gumz BP, et al. Ex vivo retrieval of mature oocytes for fertility preservation in a patient with bilateral borderline ovarian tumor. Revista Brasileira De Ginecologia e Obstetricia. 2021; 43: 225–231.
[7] Fatemi HM, Kyrou D, Al-Azemi M, Stoop D, De Sutter P, Bourgain C, et al. Ex-vivo oocyte retrieval for fertility preservation. Fertility and Sterility. 2011; 95: 1787.e15–1787.e17.
[8] Filippi F, Martinelli F, Somigliana E, Franchi D, Raspagliesi F, Chiappa V. Oocyte cryopreservation in two women with borderline ovarian tumor recurrence. Journal of Assisted Reproduction and Genetics. 2020; 37: 1213–1216.
[9] Geoffron S, Lier A, de Kermade E, Sermondade N, Varinot J, Thomassin-Naggara I, et al. Fertility preservation in women with malignant and borderline ovarian tumors: experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG). Gynecologic Oncology. 2021; 5090-8258(21)00268-7.
[10] Bourdel N, Huchon C, Abdel Wahab C, Azaïs H, Bendifallah S, Bolte P, et al. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation. Journal of Gynecology Obstetrics and Human Reproduction. 2021; 50: 101966.
[11] Franchi D, Boveri S, Radice D, Portuesi R, Zanagnolo V, Colombo N, et al. Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors. American Journal of Obstetrics and Gynecology. 2016; 215: 756.e1–756.e9.
[12] Darai E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Human Reproduction Update. 2013; 19: 151–166.
[13] Buonomo B, Peccatori FA. Fertility preservation strategies in borderline ovarian tumor recurrences: different sides of the same coin. Journal of Assisted Reproduction and Genetics. 2020; 37: 1217–1219.
[14] Jia S, Xiang Y, Yang J, Shi J, Jia C, Leng J. Oncofertility outcomes after fertility-sparing treatment of bilateral serous borderline ovarian tumors: results of a large retrospective study. Human Reproduction. 2020; 35: 328–339.
[15] Harter P, Gershenson DM, Lhomme C, Lecuru F, Ledermann J, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). International Journal of Gynecological Cancer. 2014; 24: S5–S8.
[16] Huang JYJ, Buckett WM, Gilbert L, Tan SL, Chian R. Retrieval of immature oocytes followed by in vitro maturation and vitrification: a case report on a new strategy of fertility preservation in women with borderline ovarian malignancy. Gynecologic Oncology. 2007; 105: 542–544.
[17] Morice P, Camatte S, Larregain-Fournier D, Thouy A, Duvillard P, Castaigne D. Port-site implantation after laparoscopic treatment of borderline ovarian tumors. Obstetrics and Gynecology. 2004; 104: 1167–1170.
[18] Berretta R, Rolla M, Patrelli TS, Gramellini D, Fadda GM, Nardelli GB. Incidence of port-site metastasis after laparoscopic management of borderline ovarian tumors: a series of 22 patients. European Journal of Gynaecological Oncology. 2009; 30: 300–302.
[19] Banyas-Paluchowski M, Yeganeh B, Luettges J, Maibach A, Langer Berg R, Krawczyk N, et al. Isolated subcutaneous implantation of a borderline ovarian tumor: a case report and review of the literature. World Journal of Clinical Oncology. 2016; 7: 270.